Previously, a low level of cAMP could evidently exacerbate gliomagenesis in susceptible Nf1 mice; thus, cAMP-based targeted therapy for glioma has been extensively adopted in mice [44]. This evidence concerns the gene NF1 and central nervous system cancer.